Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Mechanisms of allergic diseases

Viral infections in allergy and immunology: How allergic inflammation influences viral infections and illness

Michael R. Edwards, PhD, a,b Katherine Strong, BSc, a,b Aoife Cameron, PhD, a,b Ross P. Walton, PhD, a,b David J. Jackson, MD, PhD, a,b,c and Sebastian L. Johnston, MD, PhD a,b London, United Kingdom

Viral respiratory tract infections are associated with asthma inception in early life and asthma exacerbations in older children and adults. Although how viruses influence asthma inception is poorly understood, much research has focused on the host response to respiratory viruses and how viruses can promote; or how the host response is affected by subsequent allergen sensitization and exposure. This review focuses on the innate interferon-mediated host response to respiratory viruses and discusses and summarizes the available evidence that this response is impaired or suboptimal. In addition, the ability of respiratory viruses to act in a synergistic or additive manner with TH2 pathways will be discussed. In this review we argue that these 2 outcomes are likely linked and discuss the available evidence that shows reciprocal negative regulation between innate interferons and TH2 mediators. With the renewed interest in anti-TH2 biologics, we propose a rationale for why they are particularly successful in controlling asthma exacerbations and suggest ways in which future clinical studies could be used to find direct evidence for this hypothesis. (J Allergy Clin Immunol 2017;140:909-20.)

Key words: Virus, allergic inflammation, interferon, asthma, TH2

Viral infections are associated with asthma exacerbations (AEs) in adults and children.1 Although the mechanisms behind this association are incompletely understood, recent evidence has shown that viral infection of epithelial cells can produce cytokines, such as IL-25 and IL-33, that interact with allergic mediators and antigen-specific TH2 cell–related pathways) and resulting in increased TH2-related inflammation, eosinophilia, and enhanced allergic inflammation influences viral infections and illness.

Disclosure of potential conflict of interest: M. R. Edwards is a member of the National Medical Research Council Singapore Expert Panel and has consultant arrangements with, holds shares in, and is Scientific Director for Therapeutic Frontiers. K. Strong is employed by Asthma UK and the Medical Research Council. R. P. Walton is a board member of and has consultant arrangements with Therapeutic Frontiers Ltd. S. L. Johnston has received grants from Centocor, GlaxoSmithKline, Chiesi, Boehringer Ingelheim, Novartis, and Synairgen; has received personal fees from Centocor, Sanofi Pasteur, GlaxoSmithKline, Chiesi, Boehringer Ingelheim, Novartis, Synairgen, and Aviragen; is co-owner of a patent with Sanofi Pasteur; is a shareholder in Synairgen; is director and shareholder in Therapeutic Frontiers; has a patent (Blair ED, Killington RA, Rowlands DJ, Clarke NJ, Johnston SL, Transgenic animal models of HRV by human ICAM-1 sequences. UK patent application no. 02 167 29.4 [July 18, 2002] and international patent application no. PCT/EP2003/007939 [July 17, 2003]), licensed a patent (Wark PA, Johnston SL, Holgate ST, Davies DE. Anti-virus therapy for respiratory diseases. UK patent application no. GB 0405634.7 [March 12, 2004]), licensed a patent (Wark PA, Johnston SL, Holgate ST, Davies DE. Interferon-beta for Anti-Virus Therapy for Respiratory Diseases. International patent application no. PCT/GB05/05031 [March 12, 2004]), licensed a patent (Wark PA, Johnston SL, Holgate ST, Davies DE. The use of Interferon Lambda for the treatment and prevention of virally-induced exacerbation in asthma and chronic pulmonary obstructive disease. UK patent application no. 0518425.4 [September 9, 2005]), licensed a patent (Wark PA, Johnston SL, Holgate ST, Davies DE. Anti-virus therapy for respiratory diseases. US patent application - 11/517,763, patent no. 7596216, National Phase of PCT/GB2005/05031 [August 4, 2009]), licensed a patent (Wark PA, Johnston SL, Holgate ST, Davies DE. Interferon-beta for anti-virus therapy for respiratory diseases. European patent no. 1734987 [May 5, 2010]), licensed a patent (Wark PA, Johnston SL, Holgate ST, Davies DE. Anti-virus therapy for respiratory diseases [IFNβ therapy]. Hong Kong patent no. 1097181 [August 31, 2010]), licensed a patent (Wark PA, Johnston SL, Holgate ST, Davies DE. Anti-virus therapy for respiratory diseases [IFNb therapy]. Japanese patent no. 4807526 [August 26, 2011]), licensed a patent (Wark PA, Johnston SL, Holgate ST, Davies DE. Interferon-beta for anti-virus therapy for respiratory therapy. New Hong Kong-Divisional patent application no. 11100187.0 [January 10, 2011]), and licensed a patent (Burdin N, Almond J, Lecouturieir V, Gyéntai-Chambaz Y, Guy B, Bartlett N, et al. Induction of cross-reactive cellular response against rhinovirus antigens. European patent no. 13305152 [April 4, 2013]) pending. The rest of the authors declare that they have no relevant conflicts of interest. Received for publication June 3, 2017; revised July 20, 2017; accepted for publication July 31, 2017.

Corresponding author: Michael R. Edwards, PhD, COPD & Asthma Section, National Heart Lung Institute, Imperial College London; the MRC & Asthma UK Centre for Allergic Mechanisms of Asthma; and ‘Guy’s & St Thomas’s Hospital London.

Abbreviations used

- ACQ: Asthma Control Questionnaire
- AE: Asthma exacerbation
- AM: Alveolar macrophage
- DC: Dendritic cell
- GWAS: Genome-wide association study
- HBEC: Primary bronchial epithelial cells
- IFNAR: IFN-α receptor
- IL2: Type 2 innate lymphoid cell
- IRF: Interferon regulatory factor
- ISG: Interferon-stimulated gene
- poly I:C: Polyinosinic:polycytidylic acid
- PRR: Pattern recognition receptor
- RSV: Respiratory syncytial virus
- SOCS: Suppressor of cytokine signaling
- TLR: Toll-like receptor

The CrossMark symbol notifies online readers when updates have been made to the article such as errata or minor corrections 0091-6749 © 2017 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

http://dx.doi.org/10.1016/j.jaci.2017.07.025

Terms in boldface and italics are defined in the glossary on page 910.
IL-4, IL-5, IL-13, and mucin production. Furthermore, cells or tissues from asthmatic patients can respond to infection with a delayed and suboptimal antiviral response exemplified by delayed and deficient production of the innate interferons. Although both processes are undoubtedly important in determining disease outcomes, one idea is that these 2 outcomes are linked and that current anti-T_{H}2 biologics can function not only by reducing TH2 cytokines but also by restoring an impaired antiviral response.

This review will examine this hypothesis and discuss the evidence that supports not only impaired interferon production in asthmatic patients but also that impaired interferon production could be caused at least in part by increased T_{H}2 pathways and allergic inflammation. For simplicity, we will group allergic inflammation and T_{H}2 pathways together, although we accept that T_{H}2 cytokines might be made or might function independently of allergen exposure. This review will be limited to the discussion of impaired innate type I (IFN-α/IFN-β) and type III (IFN-λ) interferons in asthmatic patients. Some studies have shown a defective or impaired type II IFN-γ response in cells of asthmatic patients or lower T_{H}1/T_{H}2 ratios in atopic asthmatic patients versus control subjects; however, these studies will not be discussed further. Additionally, this review will focus on discussing the role of innate interferons in patients with established disease.

**GLOSSARY**

CCL5: A chemokine also known as RANTES, it has been shown to be chemotactic for T cells, eosinophils, and basophils and plays an active role in recruiting leukocytes into inflammatory sites. With the help of particular cytokines that are released by T cells, CCL5 also induces the proliferation and activation of certain natural killer cells to form CC chemokine–activated killer (CHAK) cells. It has also been shown to be an HIV-suppressive factor released from CDB+ T cells.

IFN-α: A type of human TH1 interferon protein that helps regulate the activity of the immune system. IFN-α is produced by leukocytes and has been shown to be mainly involved in the innate immune response against viral infection.

IFN-β: A type of human TH1 interferon protein produced in large quantities by fibroblasts. IFN-β displays antiviral activity in the innate immune response.

IFN-γ: A type II interferon, IFN-γ is a cytokine required for innate and adaptive immunity against viral, bacterial, and protozoal infections. IFN-γ has been shown to be an important activator of macrophages and inducer of class II major histocompatibility complex molecule expression. IFN-γ is produced predominantly by natural killer (NK) and NK T cells as part of the innate immune response and by CD4 T_{H}1 and CD8 cytotoxic T-lymphocyte effector T cells once antigen-specific immunity develops.

IFN-λ: A recently classified type III interferon group consists of 3 molecules called IFN-λ1, IFN-λ2, and IFN-λ3 (also called IL-29, IL-28A, and IL-28B, respectively). IL-28 (IFN-λ2/3) is a cytokine that comes in 2 isoforms, IL-28A and IL-28B, which play a role in innate immune defense against viruses. IL-28A and IL-28B are highly similar (in amino acid sequence) to IL-29. Both IL-28A and IL-28B have been shown to exhibit antiviral qualities and inhibit tumor cell proliferation while promoting antitumor immune responses. IL-29 is a potent antiviral cytokine through upregulation of MHC class I expression on the cell surface.

IL-4: A cytokine that induces differentiation of naive helper T cells (T_{H}0) to T_{H}2 cells. IL-4 subsequently produces additional IL-4 in a positive feedback loop. IL-4 is a ligand for the IL-4 receptor that also binds to IL-13, which contributes to many overlapping functions of IL-4 and IL-13.

IL-5: A major maturation and differentiation cytokine expressed by T_{H}2 cells and eosinophils in mice and human subjects. IL-5 has been shown to play an instrumental role in eosinophilic inflammation in patients with allergic diseases.

IL-6: A cytokine also known as IFN-j2 is implicated in a wide variety of inflammation-associated disease states. IL-6 has been associated with maturation of B cells and has been shown to act as an endogenous pyrogen capable of inducing fever in patients with autoimmune diseases or infections.

IL-13: A cytokine produced primarily by T_{H}2 cells that is involved in several stages of B-cell maturation and differentiation and is critical to the pathogenesis of allergen-induced asthma but operates through mechanisms independent of IgE and eosinophils.

IL-25: A proinflammatory cytokine that shares sequence similarity with IL-17 and has been shown to favor the T_{H}2-type immune response IL-25 activates dendritic cells and innate lymphoid cells (ILC2s).

IL-33: A member of the IL-1 family of cytokines that potently drives production of T_{H}2-associated cytokines. IL-33 is produced from epithelial cells and activates T_{H}2 cells and ILC2s.

INTERFERON REGULATORY FACTOR (IRF) 3: A member of the IRF factor family, which plays an important role in the innate immune system’s response to viral infection through induction of type I interferons.

MELANOMA DIFFERENTIATION PRIMARY RESPONSE 88 (MYD88): A universal adapter protein that functions as an essential signal transducer in the IL-1 and Toll-like receptor (TLR) signaling pathways (except TLR3). These pathways regulate activation of numerous proinflammatory genes, including the transcription factor nuclear factor κB.

RETNIC ACID–INDUCIBLE GENE (RIG) 1: A RIG-I–like receptor double-stranded DNA (dsDNA) helicase enzyme that functions as a pattern recognition receptor (recognizing long dsDNA) that is a sensor for viruses.

MYELOID DIFFERENTIATION PRIMARY RESPONSE 88 (Myd88): A cytokine that induces the activation of interferon regulatory factor 3 and nuclear factor κB.

SUPPRESSOR OF CYTOKINE SIGNALING 1 (SOCS1): Negative regulators of cytokine signaling that are members of the STAT-induced STAT inhibitor (SSI) family. Expression of this gene has been shown to be induced by a subset of cytokines, including IL-2, IL-3, erythropoietin, CSF2/GM-CSF, type I interferon, and IFN-γ.

SUPPRESSOR OF CYTOKINE SIGNALING 3 (SOCS3): Negative regulator of cytokines that signal through the Janus kinase/signal transducer and activator of transcription pathway. Expression of the SOCS3 gene is induced by various cytokines, including IL-6, IL-10, and IFN-γ.

TOLL-LIKE RECEPTOR (TLR) 3: A member of the TLR family that plays a fundamental role in pathogen recognition and activation of innate immunity. TLR3 recognizes dsRNA associated with viral infection and induces the activation of interferon regulatory factor 3 and nuclear factor κB.

TOLL-LIKE RECEPTOR (TLR) 7: A TLR that recognizes single-stranded RNA (ssRNA) in endosomes, which is a common feature of viral genomes. TLR7 recognizes ssRNA of viruses, such as HIV and hepatitis C virus, and GU-rich ssRNA.

TOLL-LIKE RECEPTOR (TLR) 8: Similar to TLR7, TLR8 endosomal receptor that recognizes single-stranded RNA (ssRNA) and can recognize ssRNA viruses, such as influenza, Sendai, and Coxackie B viruses. TLR8 binding to the viral RNA signals MyD88 and leads to activation of the transcription factor nuclear factor κB and an antiviral response. TLR8 also recognizes ssRNA of viruses, such as HIV and HCV.

The Editors wish to acknowledge Kristina Bielewicz, MS, for preparing this glossary.
asthma and will not consider the possible role of innate interferon deficiency in asthma inception in any detail.

VIRAL RESPIRATORY TRACT INFECTIONS ARE ASSOCIATED WITH ASTHMA ONSET AND AEs

The respiratory viruses associated with asthma include the same viruses that cause the common cold, influenza-like illnesses, and wheeze and bronchiolitis in children. Respiratory viruses are the main triggers of AEIs in adults and school-aged children, accounting for around 85%.8-11 Viruses associated with AEIs include respiratory syncytial virus (RSV), influenza viruses, and human rhinoviruses. Coronaviruses, parainfluenza viruses, adenoviruses, and the more recently identified metapneumoviruses and bocaviruses are also involved; however, they are less common.12,13 Both RSV and rhinoviruses have been associated with asthma inception and are strongly associated with wheeze in infants; however, the exact mechanisms remain elusive. There is some argument whether rhinoviruses and RSV cause asthma or might be markers of asthma susceptibility; it is also unclear whether both viruses act in the same manner or are subtly different. In young children RSV bronchiolitis has been linked to increased allergic sensitization14 and immune skewing to increased T\( TH_2 \) responses.15 The skewing to T\( TH_2 \) responses might reflect a way of evading protective T\( TH_1 \) responses. Although related, these topics have been thoroughly discussed elsewhere and will not be the main focus of this article; interested readers are directed to other helpful reviews.1,16,17

IMPAIRED INTERFERON EXPRESSION IN CELLS AND TISSUES FROM ASTHMATIC PATIENTS

Type I and III interferon system

Respiratory viruses are capable of infecting the bronchial epithelium of the lower airway, resulting in a local inflammatory reaction characterized by airway neutrophilia, attraction of T lymphocytes, activation of macrophages, and damage to the integrity of the bronchial epithelium.1 In an effort to limit viral spread, host cells also mount a type I (IFN-\( \alpha/\beta \)) and type III (IFN-\( \lambda \)) interferon response. Interferons are antiviral cytokines made by a wide range of cells in response to viral infection and ligation of various pattern recognition receptors (PRRs). Type I IFN-\( \alpha/\beta \) and IFN-\( \beta \) signal through the IFN-\( \alpha/\beta \) receptor (IFNAR) 1 and IFNAR2 complex, whereas type III IFN-\( \lambda \) (IFN-\( \lambda/1/IL-29 \), IFN-\( \lambda/2/IL-28A \), and IFN-\( \lambda/3/IL-28B \) in human subjects) act through the IL-10 receptor \( \beta \) chain and IFN-\( \lambda/1 \) receptor \( \alpha \) chain.16 Interferons are the first-line defense against viral infection19 and induce expression of the distinct genes termed interferon-stimulated genes (ISGs) through signaling through the type I and type III interferon receptor complexes.20,21 ISGs can be extracellular proteins, such as the T\( IFN_1 \)-attracting chemokines CXCL10 (interferon-inducible protein 10) or CXCL11 (interferon-inducible T-cell alpha chemoattractant [ITAC]), or other interferons, with IFN-\( \beta \) inducing downstream IFN-\( \alpha \) and IFN-\( \lambda \).22 Most ISGs are intracellular proteins that interfere with and thus attempt to contain viral protein trafficking, nucleic acid synthesis, or virion assembly and release. Currently, the number of known ISGs is thought to exceed 38023; however, there is the possibility of cell type–specific ISGs that are yet to be identified.

Impaired innate interferons in asthmatic patients

Rhinovirus infection induces rapid transcription of type I IFN-\( \alpha/\beta \) and type III IFN-\( \lambda \) mRNAs; however, interferon expression remains in part cell type dependent. The important signaling pathways used by rhinovirus to induce IFN-\( \beta \) and IFN-\( \lambda \) have been studied in vitro and with mouse models12,24-26 and require the PRRs melanoma differentiation factor 5, retinoic acid–inducible gene 1, Toll-like receptor (TLR) 3, TLR7, and the transcription factor interferon regulatory factor (IRF) 3. An increased susceptibility to viral infections in asthmatic patients was first reported by Corne et al.27 By studying asthmatic and nonasthmatic cohabiting spouse pairs, it was observed that both asthmatic patients and nonasthmatic subjects reported similar incidences of rhinovirus infections; however, asthmatic patients had prolonged lower respiratory tract symptoms and increased symptom severity.

In 2005, Wark et al28 cultured primary bronchial epithelial cells (HBECs) from bronchial brushings of allergic asthmatic adults and nonallergic nonasthmatic adults and challenged them with rhinovirus or treated them with the TLR3 ligand polynosinic:polycytidylic acid (poly I:C). HBECs from asthmatic patients produced lower levels of IFN-\( \beta \), had lower levels of virus-induced apoptosis, and higher rhinovirus loads over time. Proinflammatory cytokine levels (\( IL-6 \) and \( CCL5 \)) between the 2 groups were similar, and the cells from asthmatic patients produced normal levels of rhinovirus replication when pretreated with exogenous IFN-\( \beta \). The authors concluded that asthmatic patients had a specific deficiency in IFN-\( \beta \) production.

An earlier study observed impaired IFN-\( \alpha \) release in PBMCs from asthmatic patients.4 This work has since been verified by other studies and expanded to include other cell types, including dendritic cells (DCs),29 bronchoalveolar lavage fluid–derived macrophages,30 alveolar macrophages (AMs),31 and further confirmed in PBMCs.32 Furthermore, \( ex vivo \) type III IFN-\( \lambda \) levels from bronchoalveolar lavage macrophages of asthmatic patients have been shown to negatively correlate with total cold scores, changes in lung function, eosinophilia, and markers of inflammation after rhinovirus infection \( in vivo \), strongly suggesting that IFN-\( \lambda \)s are important in the pathogenesis of AEIs and determining clinical outcomes of rhinovirus infection in asthmatic patients.6

More recently, several other reports have confirmed these initial findings, including impaired interferon expression in children with severe asthma.35-37 This work culminated in the first phase II placebo-controlled clinical trial of inhaled IFN-\( \beta \) for asthma.37 This was a study of natural infections with the primary outcome of changes in Asthma Control Questionnaire (ACQ) and FEV\(_1\). Although the trial found no benefit in the primary outcome in the intent-to-treat population of 72 asthmatic patients receiving active treatment versus 75 receiving placebo, a beneficial effect was observed on peak expiratory flow (\( P = 0.033 \)), and in a subpopulation composed of patients with more severe asthma (\( n = 27 \) active and \( n = 31 \) placebo), benefit was observed in ACQ scores (\( P = 0.004 \)) and peak expiratory flow (\( P = 0.029 \)). This finding supports the premise that interferon production is indeed impaired in asthmatic patients and that restoring this defect can beneficially influence clinical disease.

The impaired interferon responses seen in patients with atopic asthma to date are likely clinically important for 2 reasons. First, impaired interferon production \( in vivo \) would not adequately con-
TABLE I. Summary of studies showing impaired or defective expression of interferon mRNA or protein in cells from asthmatic patients

| Reference       | Cell type     | Phenotype of asthma and age                          | Interferons studied | Evidence | Main findings                                                                 |
|-----------------|---------------|-----------------------------------------------------|---------------------|----------|-------------------------------------------------------------------------------|
| Bufe et al49     | PBMCs         | Atopic asthmatic children                           | IFN-α               | *, †     | First report of impaired interferon using NDV                                   |
| Wark et al51     | HBECS         | Mild atopic asthmatic adults                        | IFN-β               | *, †, §, || Associated with apoptosis and not steroid dependent                 |
| Contoli et al50  | HBECS/BAL cells | Mild atopic asthmatic adults                      | IFN-λs              | *, †     | Associated with clinical end points after experimental rhinovirus challenge   |
| Gehlhar et al52  | PBMCs         | Atopic asthmatic adults                             | IFN-α               |          | RSV and NDV                                                                    |
| Sykes et al33    | BAL cells     | Mild-to-moderate atopic asthmatic patients          | IFN-α, IFN-β        | *, †     | No impairment of critical signaling molecules, related to atopy               |
| Edwards et al56  | HBECS         | STRA atopic asthmatic children                      | IFN-β, IFN-λs       | *, †, §, || Interferon mRNA impaired to rhinovirus and poly I/C                |
| Uller et al14    | HBECS         | Mostly atopic, mixed asthma severity, adults        | IFN-β               | *, †     | TSLP levels greater in asthmatic group                                         |
| Wark et al54     | HBECS         | Moderate to severe atopic asthmatic adults          | IFN-β               |          | IFN-β protein studied only                                                     |
| Gill et al28     | Blood pDCs    | Atopic asthma adults and children                   | IFN-α               | *, †     | Influenza virus, related to IgE                                               |
| Ikura et al27    | PBMCs         | Atopic mild-to-moderate asthmatic adults and children | IFN-α               |          | Impaired IFN-α in children only also impaired proinflammatory cytokine        |
| Durrani et al29  | Blood pDCs    | Atopic asthmatic children                           | IFN-α, IFN-λs       |          | Rhinovirus, related to asthma not atopy                                         |
| Baraldo et al54  | HBECS         | Atopic and nonatopic asthmatic children              | IFN-β, IFN-λs       | *, †, §, || Associated with increased IL-4 staining, eosinophilia, and IgE in atopic subjects |
| Wagener et al56  | NECs/HBECs    | Atopic asthmatic patients                           | IFN-β, IFN-λs       |          | Poly I/C IFN-β and IL-28 mRNA expression in asthmatic patients by microarray  |
| Collison et al52 | HBECS         | Persistent asthmatic adults                         | IFN-λs              |          | No difference in intracellular viral RNA                                       |
| Spann et al55    | NECs/TECs     | Atopic children with wheeze                         | IFN-β, IFN-λs       |          | Impaired IFN-β only in NECs with RSV                                            |
| Hatchwell et al59| Bronchial biopsy specimens | Patients with moderate-to-severe eosinophilic asthma | IFN-α/β, IFN-λs     |          | Impaired IL-28 related to impaired TLR7                                         |
| Rupani et al11   | AMs           | Severe nonatopic asthma                             | IFN-α, IFN-β        |          | Identification of mir-150, 152, and 375 as associated with impaired interferons |
| Kicic et al13    | HBECS         | Atopic asthmatic children                           | IFN-β               | *, †, §, || Related to defective wound repair                                 |
| Teach et al51    | PBMCs         | Atopic asthmatic children                           | IFN-α               | *, †     | Restored by anti-IgE therapy                                                    |
| Lin et al48      | PBMCs         | Atopic asthmatic children                           | IFN-α, IFN-β        | *, †     | Impaired interferon group identified by using cluster analysis had higher rates of asthma |

RBAL, Bronchoalveolar lavage; NDV, Newcastle disease virus; NECs, nasal epithelial cells; pDCs, plasmacytoid dendritic cells; STRA, severe therapy-resistant asthma; TEC, tracheal epithelial cell; TSLP, thymic stromal lymphopoietin.

Level of evidence:

*Interferon levels in asthmatic donors were significantly lower than those of control subjects.
†Deficient interferon levels were related to clinical disease, such as number of AEs, eosinophilia, lung function, IgE levels, atopy, and T_{H2} markers.
§Significantly higher viral loads in asthmatic patients or significantly lower interferon levels that were negatively correlated with higher viral loads in asthmatic patients.
¶Exogenous IFN-β restored the antiviral response.
||Other noninterferon cytokines were not significantly different between asthmatic donors and control subjects.

Control viral infection and could lead to greater or prolonged infection, including progression and potentially the establishment of infection in the lower airway and associated virus-induced inflammation. Second, impaired interferon production might not counterregulate ongoing TH2-mediated inflammation, thus contributing to established TH2-mediated inflammation and thereby increasing disease pathogenesis and increasing risk of hospitalization, which will be discussed at length in the next section.

Limitations and controversies

Not all studies investigating impaired interferon production in asthmatic patients are in agreement, with several studies failing to show any difference in interferon production between cells from asthmatic patients and those from control subjects.38-43 Reasons for this disparity mostly concern studies of primary HBECs, which are cultured in vitro for several weeks before infection and study. Differences in the above findings are likely due to several variables, including differences in viral strains used or their preparation, cell-culture methods (eg, different components of medium), or methods of propagation, and also recruitment and phenotype of asthmatic subjects, including the asthma severity, asthma control and atopic status.40 There also exist differing strengths of evidence for these phenomena between various studies and relevance to clinical findings, such as eosinophilia, atopy, or AE rate. The findings of these studies and a description of the level of supporting evidence are summarized in Table I.1-6,28-36,44-51 Although the majority of studies use rhinovirus as a test virus, differences in interferon expression using...
other viruses have produced mixed results. Newcastle disease virus and RSV have both been used to show differences in interferon levels between groups when studying PBMCs; however, a recent side-by-side comparison of interferon responses in asthmatic patients and control subjects with RSV and influenza virus did not show impaired interferon production in HBECs from asthmatic patients. In another study differences in IFN-$\alpha$ responses in plasmacytoid dendritic cells have also been shown with influenza virus. More studies with comparisons of rhinovirus with other respiratory viruses clearly need to be performed to better understand whether the defect in interferon expression is virus specific. Likewise, studies of impaired interferon production in nasal epithelial cells from asthmatic patients have produced mixed results, suggesting that deficiency might be more profound in lower airway cells, yet deficiency is still observable in peripheral leukocyte populations. The role of atopy is perplexing; Baraldo et al showed that deficient interferon production was a feature of atopic asthmatic, nonatopic asthmatic, and nonasthmatic atopic children, and studies focusing on allergic rhinitis without asthma have produced mixed results, furthering the debate about whether it is asthma or atopy (or both) that drives this defect.

Some argue that there is controversy regarding interferon deficiency in asthmatic patients because studies investigating interferon responses in patients with stable disease or during AEs in vivo find increased rather than decreased interferon levels in asthmatic patients. However, we would argue that studies of interferon levels in vivo will be confounded by differences in viral loads and that if one wishes to investigate the presence of interferon deficiency in a disease state, this can only be done by infecting cells with a standardized quantity of virus ex vivo or stimulating cells with a standard quantity of a viral mimic ex vivo. However, enhanced rhinovirus replication in asthmatic patients during experimental challenge studies has been observed.

Gaps in our knowledge relating to the argument for impaired interferon production in asthmatic patients include (1) a lack of studies testing whether the defect is stable and repeatable in the same samples, (2) few data on asthma phenotypes other than atopic asthma, (3) a paucity of studies with viruses other than rhinovirus or a rhinovirus versus other comparison with other viruses, and (4) a lack of studies relating interferon deficiency to either asthma control at the time samples were taken or underlying asthma severity. Another limitation is that ex vivo studies use small patient numbers and a definite study of interferon expression in larger studies, such as birth cohort studies, is only beginning to be applied with impaired antiviral immunity taken into consideration.

Of note, a recent large birth cohort study identified a population of asthmatic patients with impaired interferon responses to rhinovirus at age 11 years by using cluster analysis. This group had increased wheeze in infancy and asthma at adolescence, increased AE rate, and allergic sensitization in infancy. Conversely, a subgroup of children with very low prevalence of asthma were also identified, and this group had robust interferon responses and antiviral immunity. Overall, the data strongly suggest that at least a subgroup of asthmatic patients exists with impaired interferon and antiviral immunity. However, it is possible, although currently unclear, whether asthmatic patients with impaired interferon production are a new and separate endophenotype or an important subgroup of an existing endophenotype. Despite the above differences in study design, the conflicting nature of some findings, and the above limitations, the number of studies that support the original work of Bufe et al and Wark et al continue to grow and now number approximately 20 (Table I).

**Search for mechanisms**

Our mechanistic understanding of impaired interferon responses in asthmatic patients remains poor, despite much effort. The inability to identify detailed mechanisms likely points to a complex mechanism that is not easily understood. Initially, researchers considered 2 possible explanations. First was that impaired interferon production in asthmatic patients was due to a single gene defect, microRNA, or epigenetic determinant present in asthmatic patients. This hypothesis would describe the defect as static, unchanging, and likely identifiable in genome-wide association studies (GWASs) or perhaps large gene expression data sets from next-generation sequencing approaches or protein activation data sets. The second hypothesis described a more complex gene-environment interaction that could involve a variable or even transient phenotype, immune imprinting, the actions of more than 1 gene, microRNA, or an epigenetic determinant. Thus far, databases of next-generation sequencing and microarray data have generally all failed to show a reproducible single gene defect that would explain the specific decreased expression of innate interferons observed in asthmatic patients. With the exception of TLR7 and the high-affinity receptor for the IgE chain (FcεR1) at 1q23, large published GWAS data sets on asthma again showed no obvious clue that explains these findings. The possibility still exists that a single gene defect resides in a very specific subpopulation of asthmatic patients but has been diluted in the larger studies that define asthma based on the clinical attributes or FEV$_1$ alone and often involve several hundred donors. Considering the different cell types involved (leukocytes vs structural cells), it is possible that the mechanism responsible for the defect is cell type specific. It is also possible that HBECs, because of the culture associated with their study, are more prone to lose this defect, explaining the conflicting studies that have arisen. Considering the available evidence, coupled with the failure of several HBEC studies to reproduce this defect, overall, the data argue against the single gene-hypothesis and encourage alternative hypotheses to be considered.

Two studies have identified suppressor of cytokine signaling (SOCS) 1, a negative regulator of type I and type II interferon signaling, as potentially important in determining impaired interferons in asthmatic patients. SOCS1 expression in T cells and airway smooth muscle had been linked previously to asthma; however, studies of airway epithelial cells and effects on viral responses were few. In HBECs and rhinovirus infection, T\(_7\)2 cytokines, and proinflammatory cytokines all induced SOCS1 mRNA and protein in a time-dependent manner. SOCS1, but not the closely related family member SOCS3, was observed to be of greater abundance in bronchial biopsy specimens from patients with atopic asthma, and abundance was related to PC$_{20}$ data and atopy. In a small cohort of asthmatic children with severe therapy-resistant asthma, levels of SOCS1 mRNA in unstimulated cells negatively correlated with impaired IFN-\(\beta\) and IFN-\(\lambda\) expression after rhinovirus infection and poly I:C treatment. SOCS1 can also function as a nuclear protein through a conserved
nuclear localization sequence and might interfere with gene transcription. In the same bronchial biopsy specimens, SOCS1 nuclear staining was increased in asthmatic patients, and functional studies in vitro with mutants lacking the ability to home to the nucleus did not suppress rhinovirus-induced IFN-β and IFN-α induction. The data strongly suggest that SOCS1, a virus and TH2 cytokine–inducible negative regulator that is overexpressed in allergic asthma, might be at least in part responsible for the impaired interferon levels observed. Further studies are required to support these findings, including bigger studies of SOCS1 expression in bronchial epithelium of asthmatic patients. A recent study showed reduced SOCS1 mRNA expression in bronchial biopsy specimens from patients with severe asthma compared with patients with mild-to-moderate asthma; however, immunostaining was not performed. The idea of increased SOCS1 expression in asthmatic patients remains attractive and provides a mechanistic link of how TH2 pathways can negatively regulate innate interferons.

Studying purified AMs from patients with severe asthma, Rupani et al observed impaired TLR7 expression levels with reduced rhinovirus and TLR7 ligand–induced IFN-β and IFN-α mRNA and protein levels; however, expression of other PRRs, such as TLR8, TLR3, retinoic acid–inducible gene 1, and melanoma differentiation factor 5, was not impaired. TLR7 is a single-stranded RNA receptor that uses the adaptor protein myeloid differentiation primary response 88 (MyD88) to engage a signaling apparatus leading to IRF3/7 activation and hence IFN-α/β transcription. Furthermore, TLR7 expression was inversely related to AE rate and ACQ scores, strongly suggesting that TLR7 expression levels are related to clinical asthma outcomes. Studying expression patterns of microRNAs identified several microRNAs that differed between AMs from healthy subjects and asthmatic patients, and 4 of these showed identity to the untranslated region of TLR7. Further expression analysis identified that 3 of these microRNAs, 150, 152, and 375, were significantly upregulated in AMs from asthmatic patients versus control subjects. Each microRNA was not induced by the TH2 cytokines IL-4 and IL-13, the proinflammatory cytokine TNF, and also IFN-γ and were not affected by steroid treatment. The importance of each microRNA in reducing TLR7 expression was then shown by using TLR7–specific luciferase reporters, and targeting each microRNA resulted in significantly increased interferon levels and ISG induction. Together, the data offer an important mechanistic explanation for impaired interferon in AMs from asthmatic patients.

FIG 1. Overview of additive or synergistic effects of allergen exposure and viral infection driving both pro-TH2 and IgE/TH2 inflammation. Viral infection damages the epithelial barrier and results in the pro-TH2 cytokines IL-33, IL-25, and thymic stromal lymphopoietin. These cytokines act on ILC2s, DCs, and TH2 cells, resulting in production of the TH2 cytokines IL-13, IL-4, and IL-5. These cytokines have a central role in allergic asthma: IL-4 and IL-13 drive antibody class-switching to IgE in B cells, IL-13 can act also on airway smooth muscle cells, causing bronchoconstriction and contributing to airway remodeling, and IL-5 contributes to eosinophil production. Actions of IL-4 and IL-13 and viruses on airway epithelial cells can induce the eotaxins that attract eosinophils and the chemokines macrophage-derived chemokine (MDC) and thymus and activation-regulated chemokine (TARC), which attract TH2 cells into the airway. IgE cross-linking by allergen on mast cells produces histamine, leukotrienes, and the prostaglandins PGD2 and PGE2, which further promote bronchoconstriction. PGD2 binds chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2) and activates basophils, TH2 cells, and ILC2s. Viruses can also cause oxidative stress, and pathogen-associated molecular pattern (PAMP) production can lead to the proinflammatory cytokines IL-1α/β, TNF, and IL-6. This generally results in neutrophilic inflammation and activation of macrophages. Allergen-induced IL-1α can also promote the pro-TH2 response and lead to further IL-33 production and activation of ILC2s. ENA-78, Epithelial-derived neutrophil-activating protein 78; GRO-α, melanoma growth stimulating activity-α; IL-4R, IL-4 receptor; IL-13R, IL-13 receptor; IL-25R, IL-25 receptor; IL-33R, IL-33 receptor.
patients in that decreased abundance of TLR7, an important PRR, is due to increased expression of 3 microRNAs that target the mRNA of TLR7. Although the article did not discuss why these microRNAs have increased abundance in asthmatic patients, the 3 microRNAs represent new therapeutic targets aiming to restore defective AM antiviral immunity to rhinovirus.

The significance of TLR7 has been appreciated in other studies also. Hatchwell et al identified reduced TLR7 expression in asthmatic patients in endobronchial biopsy specimens, which was related to impaired IL-28 (IFN-λ2/3) mRNA levels. Work with a mouse model showed that TLR7 can be downregulated specifically by IL-5, and TLR7 staining in endobronchial biopsy specimens was inversely related to sputum eosinophil levels. Together, these studies suggest that in leukocytes TLR7 expression or function might be a key factor determining impaired interferon production in asthmatic patients. Although these studies

---

**TABLE II.** Summary of anti-T\(_\gamma\)2 approaches and their effects on AEs and asthma-related outcomes

| Target | Agent | Reference | Main findings |
|--------|-------|-----------|---------------|
| IgE    | Antibody | Teach et al\(^{61}\) Busse et al\(^{60}\) | Reduced AE frequency and in 82 restored IFN-α responses to rhinovirus in PBMCs |
| IL-5   | Antibody | Nair et al\(^{84}\) Pavord et al\(^{89}\) Castro et al\(^{61}\) | Reductions of 52% and 58% in AE rates and increased time to AEs by 8 weeks in patients with eosinophilic asthma |
| IL-4   | Variant protein | Wenzel et al\(^{42}\) | Improved FEV\(_1\) during allergen challenge in atopic asthmatic patients |
| IL-13  | Antibody | Corren et al\(^{86}\) | Reduction of 60% in AE rate in T\(_\gamma\)2-high asthmatic patients |
| IL-5Rx | Antibody | Castro et al\(^{60}\) | Reduction of 57% in AE rate in patients with eosinophilic asthma |
| IL-4Rx | Antibody | Wenzel et al\(^{87}\) | Reduction of 87% in AE rates in patients with severe eosinophilic asthma |
| CRTH2  | Small molecule | Pettipher et al\(^{43}\) Gonen et al\(^{94}\) | Increased FEV\(_1\) and reduced eosinophilic airway inflammation in patients with eosinophilic asthma |
| GATA-3 | DNAzyme | Krug et al\(^{11}\) | Increased FEV\(_1\), reduced eosinophil numbers, and reduced IL-5 levels in patients with eosinophilic asthma |

**CRTH2**, Chemokine receptor-homologous molecule expressed on T\(_\gamma\)2 cells; IL-4Rx, IL-4 receptor α; IL-5Rx, IL-5 receptor α.

---

**FIG 2.** Summary of mechanisms of reciprocal negative regulation of type I and III interferons and T\(_\gamma\)2 pathways in asthmatic patients. T\(_\gamma\)2 cytokines can negatively regulate virus-induced interferons; cross-linking of cell-bound IgE on DCs prevents virus-induced IFN-α on infection; pretreatment of HBEcs with IL-4, IL-13, or TGF-β results in low IFN-β and IL-29 induction on infection; and IL-33 can act on DCs and reduce IRAK levels and hence IFN-α induction on infection. Interferons can suppress T\(_\gamma\)2 responses; pretreatment of T cells with IFN-α/β reduces GATA-3 and IL-5 levels in T\(_\gamma\)2 cells; viruses or TLR7 agonists produce IFN-α/β from DCs, which act on T\(_\gamma\)2 cells to reduce level of IL-4, IL-5, and IL-13; and IFN-β pretreatment of ILC2s causes a reduction in IL-4, IL-5, and IL-13. Finally, IL-28A (IFN-λ) acts on DCs to reduce OX40 ligand and prevent T\(_\gamma\)2 cell expression of IL-5 and IL-13. BECs, Bronchial epithelial cell; pDCs, plasmacytoid dendritic cells.
show clearly the important role of virus sensing by TLR7 on AMs, leading to innate interferon induction, the role of Th2 pathways on this remain incompletely resolved.

**Th2 PATHWAYS NEGATIVELY REGULATE INNATE INTERFERONS**

The Th2 cytokines IL-4, IL-5, and IL-13 are well established as effector molecules in patients with atopic asthma. Their roles are well described elsewhere and will only be summarized briefly in this review in Fig 1. Both the actions of allergens and viruses on airway epithelial and immune cells and evocation of Th2 responses are summarized in Fig 1.

**Viral infection acts additively with allergen exposure to promote AEs**

Evidence for synergy between viral infections and allergen sensitization and exposure was first identified in epidemiologic studies, and evidence for this has been extended to both human challenge studies and mouse models of rhinovirus. For RSV, several studies in mice have shown that prior exposure to RSV G protein leads to a strong Th2 response and airway eosinophilia on infection. Furthermore, mice sensitized to ovalbumin through the airway route after RSV infection had increased airway responsiveness and lung eosinophilia associated with Th2 cytokines, notably IL-5. In asthmatic patients rhinovirus infection of the bronchial epithelium also likely has additive and synergistic effects on allergen sensitization and challenge that are important in AE pathogenesis; however, a more precise understanding of how respiratory viruses can promote Th2 pathways because the mediators are induced by viral infection and their expression is consistent with clinical manifestations of asthma, asthma severity, or features of AE pathogenesis. The discovery of important pro-Th2 factors (IL-33, IL-25, and thymic stromal lymphopoietin) produced from the epithelium that induce type 2 innate lymphoid cells (ILC2s) now allows a more detailed mechanistic insight into these processes is not complete. The discovery of important pro-Th2 factors (IL-33, IL-25, and thymic stromal lymphopoietin) produced from the epithelium that induce type 2 innate lymphoid cells (ILC2s) now allows a more precise understanding of how respiratory viruses can promote Th2 pathways because the mediators are induced by viral infection and their expression is consistent with clinical manifestations of asthma, asthma severity, or features of AE pathogenesis. How viruses induced pro-Th2 factors from the epithelium and how this relates to establishing Th2 immunity are depicted in Fig 1.

**Reciprocal negative regulation between interferon and Th2 pathways**

No study has yet linked impaired interferon responses to a known asthma phenotype; however, most studies observed these phenomena to date in patients with atopic asthma. In the past, sputum eosinophil counts have been related to AE risk and impaired IFN-λs in cultured cells negatively correlated with sputum eosinophilia and both serum IgE and IL-4 staining levels in biopsy specimens. Mechanically, much evidence shows definitively that type I and III interferons and Th2 cytokines can exhibit potent negative regulation on the expression or actions of each other. IFN-α or TLR7 agonists can suppress Th2 cell polarization in pure T-cell and mixed leukocyte culture systems, downregulating levels of GATA-3, IL-4, IL-13, and IL-5. In PBMCs from atopic children, IFN-α can downregulate FcεRIα mRNA levels on both unstimulated and IL-4/IL-13–stimulated cells, highlighting a negative regulatory capacity for IFN-α on FcεRI expression. In the same experiments IFN-α increased FcεRIγ chain expression; the γ chain is involved in stabilizing FcεRIα on the cell surface and together suggests a more complex role for IFN-α in regulating atopy and IgE-mediated responses. In fact, viral induction of IFN-α in early life is thought by some to enhance FcεRIα expression on DCs and other antigen-presenting cells, likely leading to enhancement of allergic sensitization, and has been suggested as another potential mechanism how viruses contribute to the establishment of atopy. Mouse models have also been able to replicate the negative regulation on Th2 responses; IFN-λ2 (IL-28), when administered through the airways, can suppress the generation of allergic airways inflammation in an ovalbumin sensitization and challenge model in mice that is Th2 driven. This mechanism involved downregulation of OX40 ligand on DCs, leading to less Th2 cell polarization.

Recently, in a mouse model of influenza virus infection, infection of the airways with Fh11−/− mice resulted in higher levels of virus-induced lung eosinophilia, ILC2 recruitment, and higher levels of serum IgE. In comparative human studies, ILC2s cultured with IL-33 and IL-17 produced the Th2 cytokines IL-4, IL-5, IL-13, and IL-9, which were downregulated in the presence of IFN-β. This was the first study to show that, in a similar manner to Th2 cells, innate lymphoid cells are also affected by innate interferons and that their type 2 function might be increased in an environment that lacks interferon and hence this important negative regulatory mechanism. These mechanisms are shown in Fig 2.

Conversely, ex vivo and mouse model evidence strongly suggests that Th2 pathways have potent negative effects on the induction of innate interferons by viruses. For example, cross-linking FcεRI on DCs before influenza virus or rhinovirus challenge downregulates IFN-α production. Blocking IgE function with omalizumab restored this defect and reduced the rate of AEs, showing for the first time outside an experimental infection setting that ex vivo interferon measurements can predict clinical outcomes. In a mouse model of pneumovirus infection, cockroach allergen exposure in early life followed by infection led to an asthma-like phenotype with impaired lung type I and type III interferon production. In vivo, cultured, plasmacytoid dendritic cells pretreated with IL-33 showed reduced IFN-α levels on infection, along with reduced levels of IRF7, viperin, and IL-1 receptor-associated kinase 1, an important signaling molecule in TLR7 function. These data further support the importance of TLR7 expression or function in interferon interferon production in immune cells.

In HBECs pretreatment with TGF-β, IL-4, or IL-13 can reduce rhinovirus-induced IFN-β and/or IFN-α levels; this suppression is specific for interferons and does not inhibit proinflammatory cytokines, such as IL-8, which is consistent with studies of impaired interferon production in HBECs. Additionally, other non-Th2 cytokines, such as IL-2, do not have this inhibitory effect on interferons, again highlighting the unique relationship between Th2 cytokines and innate interferons, which is not simply an effect of any cytokine impairing the effect of another. Although the mechanism was not studied, it is possibly related to induced SOCS1 because SOCS1 is Th2 inducible, its levels are increased in asthmatic patients, and it is a potent negative

**INTERFERONS**

Reciprocal negative regulation between interferon and Th2 pathways is well described elsewhere and will only be summarized briefly in this review in Fig 1. Both the actions of allergens and viruses on airway epithelial and immune cells and evocation of Th2 responses are summarized in Fig 1.
regulator of virus-induced interferon production. Therefore establishing how Th2 cytokines can impair virus-induced interferons is a priority, and the mechanism could be an important therapeutic target. A summary of mechanisms responsible for Th2 pathway impairment of innate interferon production is shown in Fig 2.

Because the overall evidence strongly underscores many potential mechanisms of counterregulation of Th2 cytokines and type I and III interferons, it could be proposed that in patients with atopic or eosinophilic asthma, impaired interferon production is due to ongoing and uncontrolled Th2-mediated inflammation. The observations of increased SOCS1 levels in biopsy specimens of asthmatic patients and that SOCS1 can directly suppress interferon induction suggest a mechanism explaining why interferon levels ex vivo can be inversely associated with markers of Th2 pathways. However, it is possible that impaired interferon production might not be limited strictly to patients with eosinophilic or Th2-high asthma and that other mechanisms could explain impaired interferon expression in asthmatic patients. Considering the evidence that impaired interferon production in asthmatic patients can be associated with atopic asthma and the growing wealth of studies using anti-Th2 biologics, the above idea is a testable hypothesis, and future research should endeavor to examine the effects of Th2 biologics in clinical trials on interferon expression in asthmatic patients in vivo.

### Anti-Th2 biologics prevent AEs

The new generation of anti-Th2 biologics have shown impressive efficacy in reducing the rate of AEs in a number of studies. The different biologics and small molecules currently undergoing clinical trials are summarized in Table II. The anti–IL-13 targeting mAb lebrikizumab produced improvements in the AE rate in a subset of perisinus-high asthmatic patients. In the high-Th2 subgroup, the rate of protocol-defined exacerbations was 60% lower in the lebrikizumab group than in the placebo group (P = .03). Dupilumab, an mAb specific for the IL-4 receptor α chain, reduced AE rates by 87% in a study of patients with moderate-to-severe asthma with eosinophilia. Mepolizumab, an anti–IL-5 antibody, reduced blood and sputum eosinophil numbers in a study focusing on prednisolone-taking asthmatic patients with persistent sputum eosinophilia. Mepolizumab also significantly reduced rates of AEs and prednisolone use and improved the median time to AEs by 8 weeks. In another study of patients with eosinophilic asthma with a history of severe AEs, mepolizumab significantly reduced AE rates versus placebo up to 52%. The anti–IL-5 receptor α antibody benralizumab significantly reduced rates of AEs up to 57% in asthmatic patients with high baseline levels of eosinophils. Furthermore reslizumab, another anti–IL-5 antibody, showed a 58% reduction in AE rates, which was not significant versus placebo in patients with poorly controlled eosinophilic asthma, and pitrakinra, an IL-4 variant that inhibits IL-4/IL-13 signaling, reduced the decrease in FEV1 versus placebo during allergen challenge in atopic asthmatic patients. Small molecules targeting chemottractant receptor-homologous molecule expressed on Th2 cells have additionally shown promise increasing FEV1 and reducing eosinophilic airways inflammation and a DNazyme-targeted GATA-3 has improved FEV1 and reduced sputum eosinophil numbers and plasma IL-5 levels versus placebo in patients with eosinophilic asthma. These results are encouraging and show proof of concept that targeting Th2 pathways in atopic asthmatic patients or asthmatic patients with eosinophilia can lead to improvements in AEs.

Targeting IgE has also been shown to be effective. In a study of children and young adults with persistent asthma, omalizumab significantly reduced the proportion of participants who had 1 or more exacerbations by 18% and also reduced the number of days with asthma symptoms. Another study in asthmatic children investigated the effects of omalizumab on AE rates, and omalizumab was found to improve AE rates by approximately 5-fold. IFN-α from rhinovirus-infected PBMC cultures was also sampled before and after omalizumab treatment (4 months). Although there was no difference between omalizumab and placebo before treatment commenced, after randomization, the omalizumab group had improved IFN-α induction after rhinovirus infection, and this increase was related to the AE rate. Based on median IFN-α production in the omalizumab group, those subjects with IFN-α levels of less than the median had an almost 6-fold increase in AE rates compared with those who displayed a higher than median IFN-α response. This observation is of importance because it is the first evidence that measuring IFN-α response ex vivo can predict clinical outcomes in a clinical trial and provocatively suggests that a benefit of anti-Th2 pathway treatment might be due to restoring an impaired interferon response and increasing antiviral immunity.

### SUMMARY AND CONCLUSION

Considering the number of studies investigating innate interferon responses in asthmatic patients, interferon therapy for asthma, and the renewed appreciation for anti-Th2 pathway biologics as therapeutic interventions, we have provided a timely summary and offered important insights that might help explain the current state of this field and what will likely follow in future studies. Increased viral replication accompanied by impaired interferon production in lung cells of asthmatic patients was first observed in 2005, and since then, a number of studies have repeated these initial observations, although some have not observed this. This work culminated in the first trial of inhaled IFN-β for asthma in 2014, which showed a significant effect in a subpopulation with more severe disease.

Although the importance of impaired interferon production in asthmatic patients remains contentious and the benefit of interferon therapy is in need of confirmation, a number of important discussion points can be made from these studies. The inconsistency of some studies investigating interferon levels in asthmatic patients is likely due to subtle differences in laboratory techniques, including preparation and use of both viruses and cells, as well as patient recruitment and characterization. Furthermore, this phenotype in HBECs might be unstable. There is a paucity of studies measuring interferon levels ex vivo, and the study by Teach et al has shown that this is possible and meaningful. A further point is that future investigations of inhaled IFN-β could benefit from identifying those with impaired interferon responses as a preferred study population; however, whether this is a stable phenotype remains unproved.

The identification of SOCS1 and microRNAs 150, 152 and 375 controlling TLR7 expression remains of interest but requires confirmation. TLR7’s role in determining interferon induction in immune cells is also encouraging, tempting speculation.
that a dedicated GWAS in poor interferon responders versus good responders might be a worthwhile pursuit. Although the effects of IgE cross-linking on virus-induced interferon and the role of anti-IgE therapy open up exciting possibilities, what determines high FcεRI expression levels and the signaling apparatus that negatively regulates interferon expression is currently not known. Future research should be focused on determining this important mechanism.

Regarding anti–Th2 biologics, we have proposed herein that the benefit of these therapies on AEs, which largely have a viral cause, could be through restoration of defective antiviral immunity, thus protecting the host from more severe infections that could be through restoration of defective antiviral immunity, thus protecting the host from more severe infections that cause, could be through restoration of defective antiviral immunity, thus protecting the host from more severe infections that cause, could be through restoration of defective antiviral immunity, thus protecting the host from more severe infections that cause, could be through restoration of defective antiviral immunity, thus protecting the host from more severe infections that cause, could be through restoration of defective antiviral immunity, thus protecting the host from more severe infections that cause, could be through restoration of defective antiviral immunity, thus protecting the host from more severe infections.

REFERENCES

1. Edwards MR, Bartlett NW, Hussell T, Openshaw P, Johnston SL. The microbiology of asthma. Nat Rev Microbiol 2012;10:459-71.
2. Jackson DJ, Makrinioti H, Rana BM, Shamiy JW, Trujillo-Torrobal MB, Footit J, et al. IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo. Am J Respir Crit Care Med 2014;190:1373-82.
3. Beale J, Jayaraman A, Jackson DJ, Macintyre JD, Edwards MR, Walton RP, et al. Rhinovirus-induced IL-25 in asthma exacerbation drives type 2 immunity and allergic pulmonary inflammation. Sci Transl Med 2014;6:256ra134.
4. Buft A, Gehiak R, Grage-Griebenow E, Ernst M. Atopic phenotype in children is associated with decreased virus-induced interferon-alpha release. Int Arch Allergy Immunol 2002;127:82-8.
5. Wark PA, Johnston SL, Buciferi C, Powell R, Puddicombe S, Laza-Stanca V, et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med 2005;201:937-47.
6. Contoli M, Message SD, Laza-Stanca V, Edwards MR, Wark PA, Bartlett NW, et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med 2006;12:1023-6.
7. Message SD, Laza-Stanca V, Malin P, Parker HL, Zhu J, Kebadze T, et al. Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th2 cytokine and IL-10 production. Proc Natl Acad Sci U S A 2008;105:13562-7.
8. Johnston NW, Johnston SL, Duncan JM, Greene JM, Kebadze T, Keith PK, et al. The September epidemic of asthma exacerbations in children: a search for etiology. J Allergy Clin Immunol 2005;115:122-8.
9. Johnston SL, Pattmone PK, Sanderson G, Smith S, Lampe F, Josephs L, et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ 1995;310:1225-9.
10. Johnston SL, Pattmone PK, Sanderson G, Smith S, Campbell MJ, Josephs LK, et al. The relationship between upper respiratory infections and hospital admissions for asthma: a time-trend analysis. Am J Respir Crit Care Med 1996;154:654-60.
11. Bizzinett J, Lee WM, Laing IA, Vang F, Pappas T, Zhang G, et al. Association between human rhinovirus C and severity of acute asthma in children. Eur Respir J 2010;37:1037-42.
12. Khetsuriani N, Kazerouni NN, Erdman DD, La X, Redd SC, Anderson LJ, et al. Prevalence of viral respiratory tract infections in children with asthma. J Allergy Clin Immunol 2007;119:314-21.
13. Arden KE, Chang AB, Lambert SB, Nissen MD, Sloots TP, Mackay JM. Newly identified respiratory viruses in children with asthma exacerbation not requiring admission to hospital. J Med Virol 2010;82:1458-61.
14. Siguren B, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med 2000;161:1501-7.
39. Lopez-Souza N, Favorito S, Wong H, Ward T, Yagi S, Schmurr D, et al. In vitro susceptibility to rhinovirus infection is greater for bronchial than for nasal airway epithelial cells in human subjects. J Allergy Clin Immunol 2009;123:1384-90.e2.

40. Patel DA, Yoi Y, Huang G, Byers DE, Kim HJ, Agapov E, et al. Interferon response and respiratory viral control in nasal epithelial cells from asthma. J Allergy Clin Immunol 2014;134:1402-12.e7.

41. Batruch M, Snape N, Yeo TH, Schagen J, Thomas E, Logan J, et al. Human metapneumovirus impairs apoptosis of nasal epithelial cells in asthma via HSP70. J Innate Immun 2016;9:52-64.

42. Cakebread JA, Yu Y, Grange CC, Kehagia V, Howarth PH, Holgate ST, et al. Exogenous IFN-beta has antiviral and anti-inflammatory properties in primary bronchial epithelial cells from asthmatic subjects exposed to rhinovirus. J Allergy Clin Immunol 2011;127:1148-54.e9.

43. Sykes A, Macintyre J, Edwards MR, Del Rosario A, Haas J, Gielen V, et al. Rhinovirus-induced interferon production is not deficient in well controlled asthma. Thorax 2014;69:240-6.

44. Wark PA, Grace T, Davies B, See H, Gibson PG. Diversity in the bronchial epithelial cell response to infection with different rhinovirus strains. Respiratory 2009;14:180-6.

45. Spann KM, Batruch E, Schagen J, Jones C, Straub CP, Preston FM, et al. Viral and host factors determine innate immune responses in airway epithelial cells from children with wheeze and atopy. Thorax 2014;69:918-25.

46. Wegener AH, Zwijnderman AH, Luiten S, Fokkens WJ, Bel EH, Sterk PJ, et al. Interferon induced changes in gene expression profiles of primary nasal and bronchial epithelial cells from patients with asthma, rhinitis and controls. Respir Res 2014;15:9.

47. Ikura K, Katsuuma T, Saika S, Saito S, Ichinohe S, Ida H, et al. Peripheral blood mononuclear cells from patients with bronchial asthma show impaired innate immune responses to rhinovirus in vitro. Int Arch Allergy Immunol 2011;153(suppl 1):27-33.

48. Lin L, Belgrade D, Bakshisuli E, Hirsman A, Edwards MR, Walton RP, et al. Phenotyping immune responses in asthma and respiratory infections. San Francisco: Proceedings of the American Thoracic Society Conference; 2016 May 13-18:A7870.

49. Hatchwell L, Collison A, Girkin J, Parsoms K, Li J, Zhang J, et al. Toll-like receptor 7 governs interferon and inflammatory responses to rhinovirus and is suppressed by IL-5-induced lung eosinophilia. Thorax 2015;70:854-61.

50. Collison A, Hatchwell L, Verrills N, Wark PA, de Siqueira AP, Tooze M, et al. The E3 ubiquitin ligase midline 1 promotes allergen and rhinovirus-induced asthma by inhibiting protein phosphatase 2A activity. Nat Med 2013;19:232-7.

51. Tebbey PW, Hagen M, Hancock GE. Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus. J Exp Med 1998;187:1921-6.

52. Bartlett NW, Walton RP, Edwards MR, Aniscenko J, Caramori G, Zhu J, et al. Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. Nat Med 2008;14:199-204.

53. Sparer TE, Matthews S, Russell T, Rae AJ, Garcia-Barreno B, Melero JA, et al. Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia. J Exp Med 1998;187:1921-6.

54. Huber JP, Ramos HJ, Gill MA, Farrar JD. Cutting edge: type I IFN reverses human Th2 cytokine responses to rhinovirus: a regulatory mechanism with relevance to asthma. J Immunol 2010;184:813-7.

55. Edwards S, Jones C, Leishman AJ, Young BW, Matsui H, Tomizawa H, et al. Asthma exacerbations and systemic eosinophil counts: a randomised controlled trial. Lancet 2002;360:1715-21.

56. Pritchard AL, Carroll ML, Burel JG, White OJ, Phipps S, Upham JW. Innate IFNs and plasmacytoid dendritic cells constrain Th2 cytokine responses to rhinovirus: a regulatory mechanism with relevance to asthma. J Allergy Clin Immunol 2015;136:177-88.e11.

57. Möller-Larsen S, Nyegaard M, Haagrup A, Vestbo J, Borghum AD. Association analysis identifies TLR7 and TLR8 as novel risk genes in asthma and related disorders. Thorax 2008;63:1064-9.

58. Sharma V, Michel S, Gaertner V, Franke A, Vogelberg C, von Berg A, et al. Fine-mapping of IgE-associated loci 1q23, 5q31, and 12q13 using 1000 Genomes Project data. Allergy 2014;69:1077-84.
84. Thomas BJ, Lindsay M, Dagher H, Freezer NJ, Li D, Ghildyal R, et al. Transforming growth factor-beta enhances rhinovirus infection by diminishing early innate responses. Am J Respir Cell Mol Biol 2009;41:339-47.
85. Contoli M, Ito K, Padovani A, Poletti D, Marka B, Edwards MR, et al. Th2 cytokines impair innate immune responses to rhinovirus in respiratory epithelial cells. Allergy 2015;70:910-20.
86. Corren J, Lemanske RF, Hanania NA, Korenbrot PE, Parsey MV, Arron JR, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365:1088-98.
87. Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skoberne A, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013;368:2455-66.
88. Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360:985-93.
89. Pavord ID, Korn S, Howarth P, Blecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651-9.
90. Castro M, Wenzel SE, Blecker ER, Pizzichini E, Kuna P, Busse WW, et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med 2014;2:879-90.
91. Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011;184:1125-32.
92. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007;370:1422-31.
93. Pettipher R, Hunter MG, Perkins CM, Collins LP, Lewis T, Baille M, et al. Heightened response of eosinophilic asthmatic patients to the CTH2 antagonist OC000459. Allergy 2014;69:1223-32.
94. Gomes S, Berair R, Singapuri A, Hartley R, Laurencin MF, Bacher G, et al. Fvipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med 2016;4:699-707.
95. Krug N, Hohlfeld JM, Kirsten AM, Kornmann O, Beenh K, Kappeler D, et al. Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. N Engl J Med 2015;372:1987-95.
96. Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 2011;364:1005-15.